Understanding DNA repair mechanisms has significant therapeutic implications. For instance, drugs that inhibit PARP (poly ADP-ribose polymerase), an enzyme involved in repairing SSBs, are effective in treating cancers with BRCA mutations. These drugs work by exploiting the concept of synthetic lethality, where the inhibition of PARP leads to the accumulation of DSBs, causing cell death in cancer cells deficient in HR.
